- Home
- CIFR vs SPRY Comparison
CIFR vs SPRY Comparison
Compare CIFR & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- SPRY
- Stock Information
- Founded
- CIFR 2021
- SPRY 2015
- Country
- CIFR United States
- SPRY United States
- Employees
- CIFR N/A
- SPRY N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- CIFR Finance
- SPRY Health Care
- Exchange
- CIFR Nasdaq
- SPRY Nasdaq
- Market Cap
- CIFR 2.1B
- SPRY 1.8B
- IPO Year
- CIFR N/A
- SPRY N/A
- Fundamental
- Price
- CIFR $6.68
- SPRY $18.00
- Analyst Decision
- CIFR Strong Buy
- SPRY Strong Buy
- Analyst Count
- CIFR 11
- SPRY 4
- Target Price
- CIFR $7.58
- SPRY $28.75
- AVG Volume (30 Days)
- CIFR 49.7M
- SPRY 1.4M
- Earning Date
- CIFR 08-07-2025
- SPRY 08-05-2025
- Dividend Yield
- CIFR N/A
- SPRY N/A
- EPS Growth
- CIFR N/A
- SPRY N/A
- EPS
- CIFR N/A
- SPRY N/A
- Revenue
- CIFR $152,092,000.00
- SPRY $97,122,000.00
- Revenue This Year
- CIFR $87.55
- SPRY N/A
- Revenue Next Year
- CIFR $68.51
- SPRY $170.64
- P/E Ratio
- CIFR N/A
- SPRY N/A
- Revenue Growth
- CIFR N/A
- SPRY 971120.00
- 52 Week Low
- CIFR $1.86
- SPRY $8.91
- 52 Week High
- CIFR $7.77
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- CIFR 69.33
- SPRY 59.29
- Support Level
- CIFR $5.95
- SPRY $17.19
- Resistance Level
- CIFR $7.10
- SPRY $18.61
- Average True Range (ATR)
- CIFR 0.56
- SPRY 0.76
- MACD
- CIFR 0.03
- SPRY -0.07
- Stochastic Oscillator
- CIFR 77.05
- SPRY 75.20
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.